^
    No biomarker
    Hairy Cell Leukemia
    cladribine
    Sensitive: A1 - Approval
    No biomarker
    Hairy Cell Leukemia
    moxetumomab pasudotox
    Sensitive: A1 - Approval
    No biomarker
    Hairy Cell Leukemia
    rituximab
    Sensitive: A2 - Guideline
    No biomarker
    Hairy Cell Leukemia
    rituximab
    Sensitive: A2 - Guideline
    No biomarker
    Hairy Cell Leukemia
    vemurafenib + rituximab
    Sensitive: A2 - Guideline
    No biomarker
    Hairy Cell Leukemia
    pentostatin
    Sensitive: A2 - Guideline
    No biomarker
    Hairy Cell Leukemia
    rituximab / hyaluronidase
    Sensitive: A2 - Guideline
    No biomarker
    Hairy Cell Leukemia
    rituximab
    Sensitive: A2 - Guideline
    No biomarker
    Hairy Cell Leukemia
    vemurafenib
    Sensitive: A2 - Guideline
    No biomarker
    Hairy Cell Leukemia
    ibrutinib
    Sensitive: A2 - Guideline
    BRAF V600E
    Hairy Cell Leukemia
    dabrafenib
    Sensitive: C2 – Inclusion Criteria
    BRAF V600
    Hairy Cell Leukemia
    vemurafenib
    Sensitive: C2 – Inclusion Criteria
    BRAF V600E
    Hairy Cell Leukemia
    vemurafenib
    Sensitive: C2 – Inclusion Criteria
    BRAF V600E
    Hairy Cell Leukemia
    dabrafenib + rituximab
    Sensitive: C3 – Early Trials
    TP53 mutation
    Hairy Cell Leukemia
    rituximab + cladribine
    Resistant: C3 – Early Trials
    MYD88 L265P + BRAF V600E
    Hairy Cell Leukemia
    rituximab
    Sensitive: C4 – Case Studies
    KRAS mutation
    Hairy Cell Leukemia
    vemurafenib
    Resistant: C4 – Case Studies